2 HIV drugs from Gilead's Stribild fail to win FDA approval as standalones

04/30/2013 | MedCityNews.com

The FDA turned down Gilead Sciences' regulatory applications for elvitegravir and cobicistat as standalone treatments for HIV, citing problems in certain quality testing procedures. The two drugs are included in Gilead's 4-in-1 HIV pill Stribild, which was approved by the FDA last year. Gilead says it is working with the agency to address the issues mentioned in the rejection letter.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY